NCT03917992 is a clinical trial in Atrial Fibrillation, sponsored by Ayman J Hammoudeh, MD, FACC.

Who is sponsoring NCT03917992?

NCT03917992 is sponsored by Ayman J Hammoudeh, MD, FACC.

What condition does NCT03917992 study?

NCT03917992 studies Atrial Fibrillation.

Is NCT03917992 still recruiting?

NCT03917992 is currently completed. Last updated 25 May 2023.

Last reviewed 2023-05-25 · How we verify

NCT03917992

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Jordan Atrial Fibrillation Study: Baseline Risk Scores and One Year Outcome

Completed Last updated 25 May 2023

What this trial tests

trial in Atrial Fibrillation in 2,020 participants. Completed in 25 November 2021.

Timeline

25 May 2019

Primary endpoint
25 November 2021

25 November 2021

Quick facts

Lead sponsor	Ayman J Hammoudeh, MD, FACC
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,020
Start date	25 May 2019
Primary completion	25 November 2021
Estimated completion	25 November 2021
Sites	8 locations across Jordan

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →

Sponsor

Ayman J Hammoudeh, MD, FACC

Who can join

18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Jordanian AF study, the first of its kind in Jordan, will evaluate patients with AF in an in-patient and out-patient settings. The morbidity and mortality associated with AF has not been studied in this region especially with the relation to the HAD BLED and CHADS VAC score.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

One-Year Clinical Outcome in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study.
Hammoudeh A, Khader Y, Tabbalat R, Badaineh Y, et al · · 2022 · cited 13× · PMID 35462945 · DOI 10.1155/2022/4240999
Adherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study.
Hammoudeh AJ, Khader Y, Kadri N, Al-Mousa E, et al · · 2021 · cited 12× · PMID 33898065 · DOI 10.1155/2021/5515089
Impact of thyroid disease in patients with atrial fibrillation: Analysis from the JoFib registry.
Al-Makhamreh H, Al-Ani A, Alkhulaifat D, Shaban L, et al · · 2022 · cited 7× · PMID 35145683 · DOI 10.1016/j.amsu.2022.103325
Validation of CHA2DS2 VASc Score Predictability of Stroke and Systemic Embolization in a Middle Eastern Population with AF: The Jordan Atrial Fibrillation (JoFib) Study.
Ibdah R, Obeidat O, Khader Y, Al-Nusair J, et al · · 2023 · cited 6× · PMID 37125391 · DOI 10.2147/vhrm.s404575
Paroxysmal and Non-Paroxysmal Atrial Fibrillation in Middle Eastern Patients: Clinical Features and the Use of Medications. Analysis of the Jordan Atrial Fibrillation (JoFib) Study.
Al-Makhamreh H, Alrabadi N, Haikal L, Krishan M, et al · · 2022 · cited 4× · PMID 35627709 · DOI 10.3390/ijerph19106173
Prevalence, Epidemiological Characteristics, and Pharmacotherapy of Coronary Artery Disease among Patients with Atrial Fibrillation: Data from Jo-Fib Study.
Al-Makhamreh HK, Al-Sabbagh MQ, Shaban AE, Obiedat AF, et al · · 2021 · cited 4× · PMID 34208175 · DOI 10.3390/medicina57060605
Absence of Standard Modifiable Risk Factors in Middle Eastern Patients with Atherosclerotic Cardiovascular Disease. The Jordan Absence of Standard Modifiable Risk Factors (SMuRF-Less) Study.
Hammoudeh AJ, Aldalal'ah M, Smadi EA, Alrishoud D, et al · · 2025 · cited 3× · PMID 39931041 · DOI 10.2147/vhrm.s499355
Factors Associated with Quality of Life among People with Atrial Fibrillation: Jordan Atrial Fibrillation Registry Study.
Al-Bashaireh AM, Alkouri O, Alharbi A, Khader Y, et al · · 2024 · cited 3× · PMID 39202543 · DOI 10.3390/medicina60081262

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03917992 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ayman J Hammoudeh, MD, FACC
Last refreshed: 25 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03917992.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing